

New products and services briefing

Listings are prepared from information supplied by the companies cited or by their agents and are presented for informational value only. Publication in no way constitutes endorsement or warranty by The Journal of the American Osteopathic Association. In contacting these companies, please mention JAOA.

Dissociated vertical deviation may also be diagnosed with greater accuracy using this instrument. The device can be mounted to a compatible power source. For more information, contact Welch Allyn, Inc, Medical Division, 4341 State St Rd, PO Box 220, Skaneateles Falls, NY 13153-0220; (800) 535-6663, or (315) 685-4560.

This broad-spectrum antibiotic is intended to treat lower respiratory tract infections, skin and skin structure infections, prostatitis, and urinary tract infections. The antibiotic is available in 400-mg and 600-mg tablets. For more information, contact Abbott Laboratories, One Abbott Park Rd, Abbott Park, IL 60064-3500; (708) 937-5968.

Allergy, asthma monitoring protein

Intended for use in research only, the Pharmacia Eosinophil Cationic Protein (ECP) test is an in vitro assay used to detect eosinophil activity levels in serum. The test is a 1-day, double-antibody radioimmunoassay procedure. Reagents are available in a 50-test kit. For more information, contact Pharmacia Diagnostics Inc, 350 Passaic Ave, Fairfield, NJ 07004; (800) 346-4364, or (201) 227-6700.

Strabismus detector

Featuring a semisilvered mirror and a 3.5-volt Halogen lamp, the Strabismoscope is used to perform the cover test to detect strabismus. When illuminated, the mirror in this ophthalmologic instrument reflects most of the incident light, transmitting the rest.

Hand-held obstetrics doppler

The Imex Pocket-DOP 3[®] features a hand-held obstetric doppler with autocorrelation and an average mode that quickly displays the fetal heart rate in large high-contrast numbers. The doppler can be mounted on a wall or recharged using countertop recharging stand. The doppler has interchangeable probes and a magnetic probe holder. For more information, contact Imex Medical Systems, Inc, 6355 Joyce Dr, Golden, CO 80403; (800) 525-2519, or (303) 431-9400.

Broad-spectrum antibiotic

Omniflox (temafloxacin hydrochloride) is active against gram-negative and gram-positive aerobes, anaerobic bacteria, and other organisms, such as *Chlamydia trachomatis*.

SURGICAL RESIDENTS/FELLOWS

Clinical residency/fellowship positions available in adult and pediatric cardiothoracic surgery.

- Large volume of cases
 New Jersey license required
- •Excellent salary and benefits


Please contact:

Lynn B. McGrath, MD Chairman, Dept. of Surgery (609) 893-6611, Ext. 359




Deborah Heart and Lung Center 200 Trenton Road Browns Mills, NJ 08015

Make this connection to reduce heart attack risk




To reduce heart attack risk, don't overlook coexisting low HDL, high triglycerides, and high LDL. A recently published analysis of data from a Helsinki Heart Study subgroup shows why:

LOPID reduced the incidence of heart attack* 71%



—in a high-risk subgroup of patients with multiple lipid disorders. While the overall reduction in heart attack was 34%, the greatest reduction in heart attack was achieved among those LOPID patients with baseline triglycerides >200 mg/dL and baseline LDL/HDL >5 (n = 154).^{†1}





TREATS THE ENTIRE TRIAD DRAMATICALLY REDUCES HEART ATTACK

LOPID is indicated for reducing the risk of coronary heart disease in type IIb patients with low HDL, in addition to elevated LDL and triglycerides, and who have had an inadequate response to weight loss, diet, exercise, and other pharmacologic agents such as bile acid sequestrants and nicotinic acid. LOPID is not indicated for the treatment of patients with low HDL as their only lipid abnormality.


Contraindicated in patients with hepatic or severe renal dysfunction, including primary biliary cirrhosis, preexisting gallbladder disease, or hypersensitivity to gemfibrozil. LOPID may increase cholesterol secretion into the bile, leading to cholelithiasis. Caution should be exercised when anticoagulants are given in conjunction with LOPID.

Reference 1. Manninen V, Tenkanen L, Koskinen P, et al. Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study: implications for treatment. *Circulation*. 1992;85:37-45.


*Defined as a combination of definite coronary death and/or definite myocardial infarction.

†Mean HDL = 35 mg/dL; mean LDL = 208 mg/dL; P = .005; 95 % CI 21.2 to 118.6.

Please see last page of this advertisement for warnings, contraindications, and brief summary of prescribing information.







Lopid® (Gemfibrozil Capsules and Tablets)

Before prescribing, please see full prescribing information. A Brief Summary follows.

CONTRAINDICATIONS. 1. Hepatic or severe renal dysfunction, including primary biliary cirrhosis.
2. Preexisting gallbladder disease (See WARNINGS)

Hypersensitivity to gemfibrozil.

WARNINGS. 1. Because of chemical, pharmacological, and clinical similarities between gemfibrozil and clofibrate, the adverse findings with clofibrate in two large clinical studies may also apply to gemfibrozil. In the first of those studies, the Coronary Drug Project, 1000 subjects with previous myocardial infarction were treated for five years with clofibrate. There was no difference in mortality between the clofibrate-treated subjects and 3000 placebo-treated subjects, but twice as many clofibrate-treated subjects developed cholelithiasis and cholecystitis requiring surgery. In the other study, conducted by the World Health Organization (WHO), 5000 subjects without known coronary heart disease were treated with clofibrate for five years and followed one year beyond. There was a statistically significant, 29%, higher total mortality in the clofibrate-treated than in a comparable placebo-treated control group. The excess mortality was due to a 33% increase in noncardiovascular causes, including malignancy, post-cholecystectomy complications, and pancreatitis. The higher risk of clofibrate-treated

subjects for gallbladder disease was confirmed.

During the Helsinki Heart Study and in the 1½ year follow-up period since the trial was completed, mortality from any cause was 59 (2.9%) in the Lopid group and 55 (2.7%) in the placebo group. Mortality from any cause during the double-blind portion of the study was 44 deaths in the Lopid group and 43 in the placebo group. Because of the more limited size of the Helsinki Heart Study, this result is not statisticallythe more limited size of the Heisinki Heart Study, this result is not statistically-significantly different from the 29% excess mortality seen in the clofibrate group in the separate WHO study. Noncoronary heart disease related mortality showed a 58% greater trend in the Lopid group (43 vs 27 patients in the placebo group, p=0.056). In the Helsinki Heart Study, the incidence of total malignancies discovered during the

trial and in the 11/2 years since the trial was completed was 39 in the Lopid group and 29 in the placebo group (difference not statistically significant). This includes 5 basal cell carcinomas in the Lopid group and none in the placebo group (p=0.06; historical data predicted an expected 4.7 cases in the placebo group). GI malignancies and deaths

from malignancies were not statistically different between Lopid and placebo subgroups. Follow-up of the Helsinki Heart Study participants will provide further information on cause-specific mortality and cancer morbidity.

2. A gallstone prevalence substudy of 450 Helsinki Heart Study participants showed a trend toward a greater prevalence of gall-stones during the study within the Lopid treatment group (7.5% vs 4.9% for the placetreatment group (7.5% vs 4.9% for the placebo group, a 55% excess for the gemfibrozil
group). A trend toward a greater incidence
of gallbladder surgery was observed for the
Lopid group (17 vs 11 subjects, a 54% excess). This result did not differ statistically
from the increased incidence of cholecystectomy observed in the WHO study in the
group treated with clofibrate. Both clofibrate and gemfibrozil may increase cholesterol

excretion into the bile leading to cholelithiasis. If cholelithiasis is suspected, gallbladder

studies are indicated. Lopid therapy should be discontinued if gallstones are found.

3. Since a reduction of mortality from coronary artery disease has not been demonstrated and because liver and interstitial cell testicular tumors were increased in rats, Lopid should be administered only to those patients described in the INDICATIONS AND USAGE section. If a significant serum lipid response is not obtained, Lopid should be discontinued.

4. Concomitant Anticoagulants — Caution should be exercised when anticoagulants are given in conjunction with Lopid. The dosage of the anticoagulant should be reduced to maintain the prothrombin time at the desired level to prevent bleeding complications. Frequent prothrombin determinations are advisable until it has been definitely determined that the prothrombin level has stabilized.

5. Concomitant therapy with Lopid and Mevacor® (lovastatin) has been associated with rhabdomyolysis, markedly elevated creatine kinase (CK) levels and myoglobinuria, leading in a high proportion of cases to acute renal failure. In most subjects who have had an unsatisfactory lipid response to either drug alone, the possible benefit of combined therapy with lovastatin and gemfibrozil does not outweigh the risks of severe myopathy, rhabdomyolysis, and acute renal failure (See Drug Interactions). The use of fibrates alone, including Lopid, may occasionally be associated with myositis. Patients receiving Lopid and complaining of muscle pain, tenderness, or weakness should have prompt medical evaluation for myositis, including serum creatine kinase level determination. If myositis is suspected or diagnosed, Lopid therapy should be withdrawn.

6. Cataracts – Subcapsular bilateral cataracts occurred in 10%, and unilateral in 6.3%

of male rats treated with gemfibrozil at 10 times the human dose. PRECAUTIONS. 1. Initial Therapy — Laboratory studies should be done to ascertain that the lipid levels are consistently abnormal. Before instituting Lopid therapy, every attempt should be made to control serum lipids with appropriate diet, exercise, weight loss in obese patients, and control of any medical problems such as diabetes mellitus and

hypothyroidism that are contributing to the lipid abnormalities.

2. Continued Therapy — Periodic determination of serum lipids should be obtained, and the drug withdrawn if lipid response is inadequate after 3 months of therapy.

3. Drug Interactions - (A) Lovastatin: Rhabdomyolysis has occurred with combined gemfibrozil and lovastatin therapy. It may be seen as early as 3 weeks after initiation of combined therapy or after several months. In most subjects who have had an unsatisfactory lipid response to either drug alone, the possible benefit of combined therapy with

tory lipid response to eitner drug alone, the possible benefit of combined therapy with lovastatin and gemfibrozil does not outweigh the risks of severe myopathy, rhab-domyolysis, and acute renal failure. There is no assurance that periodic monitoring of creatine kinases will prevent the occurrence of severe myopathy and kidney damage. (B) Anticoagulants: CAUTION SHOULD BE EXERCISED WHEN ANTICOAGULANTS ARE GIVEN IN CONJUNCTION WITH LOPID. THE DOSAGE OF THE ANTICOAGULANT SHOULD BE REDUCED TO MAINTAIN THE PROTHROMBIN TIME AT THE DESIRED I EVEL TO PREVENT RIFEDING COMPUCATIONS FREQUENT THE DESIRED LEVEL TO PREVENT BLEEDING COMPLICATIONS. FREQUENT PROTHROMBIN DETERMINATIONS ARE ADVISABLE UNTIL IT HAS BEEN DEFINITELY DETERMINED THAT THE PROTHROMBIN LEVEL HAS STABILIZED.

 Carcinogenesis, Mutagenesis, Impairment of Fertility – Long-term studies have been conducted in rats and mice at one and ten times the human dose. The incidence of benign liver nodules and liver carcinomas was significantly increased in high dose male rats. The incidence of liver carcinomas increased also in low dose males but this increase was not statistically significant (p=0.1). In high dose female rats, there was a significant increase in the combined incidence of benign, and malignant liver neoplasms. In male and female mice, there were no statistically significant differences

Lopid® (Gemfibrozil Capsules and Tablets)

from controls in the incidence of liver tumors, but the doses tested were lower than those shown to be carcinogenic with other fibrates

Male rats had a dose-related and statistically significant increase of benign Leydig cell tumors at 1 and 10 times the human dose.

Electron microscopy studies have demonstrated a florid hepatic peroxisome proliferation following Lopid administration to the male rat. An adequate study to test for perox isome proliferation has not been done in humans but changes in peroxisome morphology have been observed. Peroxisome proliferation has been shown to occur in humans with either of two other drugs of the fibrate class when liver biopsies were compared before and after treatment in the same individual.

Administration of approximately three or ten times the human dose to male rats for 10 weeks resulted in a dose-related decrease of fertility. Subsequent studies demonstrated that this effect was reversed after a drug-free period of about eight weeks, and it was not transmit-

ted to the offspring.

5. Pregnancy Category B — Reproduction studies have been performed in the rat at doses 3 and 9 times the human dose, and in the rabbit at 2 and 6.7 times the human dose, and in the rabbit at 2 and 6.7 times the human dose, and in the rabbit at 2 and 6.7 times the human dose. dose. These studies have revealed no evidence of impaired fertility in females or harm to the fetus due to Lopid. Minor fetotoxicity was manifested by reduced birth rates observed at the high dose levels. No significant malformations were found among almost 400 offspring from 36 litters of rats and 100 fetuses from 22 litters of rabbits.

There are no studies in pregnant women. In view of the fact that Lopid is tumorigenic in male and female rats, the use of Lopid in pregnancy should be reserved for those patients where the benefit clearly outweighs the possible risk to the patient or fetus.

6. Nursing Mothers — Because of the potential for tumorigenicity shown for gem-

fibrozil in rats, a decision should be made whether to discontinue nursing or discontinue

the drug, taking into account the importance of the drug to the mother.

7. Hematologic Changes — Mild hemoglobin, hematocrit and white blood cell decreases have been observed in occasional patients following initiation of Lopid therapy. However, these levels stabilize during long-term administration. Rarely, severe anemia, leukopenia, thrombocytopenia, and bone marrow hypoplasia have been reported. Therefore, periodic blood counts are recommended during the first 12 months of Lopid administration.

8. Liver Function — Abnormal liver function tests have been observed occasionally during Lopid administration, including elevations of AST (SGOT), ALT (SGPT), LDH, bili-

rubin, and alkaline phosphatase. These are usually reversible when Lopid is discontinued. Therefore periodic liver function studies are recommended and Lopid therapy should be terminated if abnormalities persis

Use in Children – Safety and efficacy in children have not been established. ADVERSE REACTIONS. In the double-blind controlled phase of the Helsinki Heart Study, 2046 patients received Lopid for up to 5 years. In that study, the following adverse reactions were statistically more frequent in subjects in the Lopid group (placebo incidence in paren-

(23.8%); dyspepsia, 19.6% (11.9%); abdominal pain, 9.8% (56%); acute appendicitis (histologically confirmed in most cases where data are available), 1.2% (0.6%); atrial fibrillation, 0.7% (0.1%).

Adverse events reported by more than 1% of subjects, but without a significant difference between groups (placebo incidence in parentheses) were: diarrhea, 7.2% (6.5%); fatigue, 3.8% (3.5%); nausea/vomiting, 2.5% (2.1%); eczema, 1.9% (1.2%); rash, 1.7% (1.3%); vertigo, 1.5% (1.3%); constipation, 1.4% (1.3%); beadache, 1.2% (1.2%), fash, 1.7% (1.3%); vertigo, 1.5% (1.3%); constipation, 1.4% (1.3%); headache, 1.2% (1.1%).

Gallbladder surgery was performed in 0.9% of Lopid and 0.5% of placebo subjects, a 64% excess, which is not statistically different from the excess of gallbladder surgery observed in the clofibrate compared to the placebo group of the WHO study.

Nervous system and special senses adverse reactions were more common in the Lopid group. These included hypesthesia, paresthesias, and taste perversion. Other adverse reactions that were more common among Lopid treatment group subjects but where a causal relationship was not established include cataracts, peripheral vascular

disease, and intracerebral hemorrhage.

From other studies it seems probable that Lopid is causally related to the occurrence of musculoskeletal symptoms (See WARNINGS), and to abnormal liver function

tests and hematologic changes (See PRECAUTIONS).

Reports of viral and bacterial infections (common cold, cough, urinary tract infections) were more common in gemfibrozil-treated patients in other controlled clinical trials of 805 patients. Additional adverse reactions that have been reported for gemfibrozil are listed below

by system. These are categorized according to whether a causal relationship to treat-

ment with Lopid is probable or not established: CAUSAL RELATIONSHIP PROBABLE: Gastrointestinal: cholestatic jaundice; Central Nervous System: dizziness, somnolence, paresthesia, peripheral neuritis, decreased libido, depression, headache; Eye: blurred vision; Genitourinary: impotence; Musculoskeletal: myopathy, myasthenia, myalgia, painful extremities, arthralgia, synovitis, rhabdomyolysis (see WARNINGS and Drug Interactions under PRECAUTIONS); Clinical Laboratory: increased creatine phosphokinase, increased bilirubin, increased liver transaminases (AST [SGOT], ALT [SGPT]), increased alkaline phosphatase; Hamatonicitic; acemia, bette marrow by morphisms and spinophilis; Iransaminases (AST [SGOT], ALT [SGPT]), increase displaying the phosphatase; Hematopoietic: anemia, leukopenia, bone marrow hypoplasia, eosinophilia; Immunologic: angioedema, laryngeal edema, urticaria; Integumentary: exfoliative der

munologic: angioedema, laryngeal edema, urticaria; Integumentary: extoliative dermatitis, rash, dermatitis, pruritus.

CAUSAL RELATIONSHIP NOT ESTABLISHED: General: weight loss; Cardiac: extrasystoles; Gastrointestinal: pancreatitis, hepatoma, colitis; Central Nervous System: confusion, convulsions, syncope; Eye: retinal edema; Genitourinary: decreased male fertility; Clinical Laboratory: positive antinuclear antibody; Hematopoietic: thrombocytopenia; Immunologic: anaphylaxis, Lupus-like syndrome, vasculitis; Integumentary: alopecia.

DOSAGE AND ADMINISTRATION. The recommended dose for adults is 1200 mg administered in two divided doses 30 minutes before the morning and evening meal.

MANAGEMENT OF OVERDOSS. While they has been no reported case of over-MANAGEMENT OF OVERDOSE. While there has been no reported case of overdosage, symptomatic supportive measures should be taken should it occur. **References:** 1. Frick MH, Elo O, Haapa K, et al: Helsinki Heart Study: Primary prevention trial with gemfibrozil in middle-aged men with dyslipidemia. *N Engl J Med* 1987;317:1237-1245. 2. Manninen V, Elo O, Frick MH, et al: Lipid alterations and decline

in the incidence of coronary heart disease in the Helsinki Heart Study. *JAMA* 1988; 260:641-651. 3. Nikkila EA: Familial lipoprotein lipase deficiency and related disorders of chylomicron metabolism. In Stanbury J. B. et al. (eds.): *The Metabolic Basis of Inherited Disease*, 5th ed., McGraw-Hill, 1983, Chap. 30, pp. 622-642.

Caution — Federal law prohibits dispensing without prescription.

PARKE-DAVIS Morris Plains, NJ 07950 USA

0737G013 PD-56-IA-7581-A1(022)



RAISES HDL, LOWERS LDL AND TRIGLYCERIDES DRAMATICALLY REDUCES HEART ATTACK